support glp 1 GLP-1 Support | Appetite support for cravings and fullness control

Connecticut is moving to eliminate Medicaid coverage of GLP-1 weight loss drugs like Ozempic and Mounjaro, a decision that could leave thousands of residents without access to medications that have transformed obesity

21.84

★★★★☆4.8 (126)

Connecticut is moving to eliminate Medicaid coverage of GLP-1 weight loss drugs like Ozempic and Mounjaro, a decision that could leave thousands of residents without access to medications that have transformed obesity

28.59

★★★★★4.9 (98)

Connecticut is moving to eliminate Medicaid coverage of GLP-1 weight loss drugs like Ozempic and Mounjaro, a decision that could leave thousands of residents without access to medications that have transformed obesity

26.46

★★★★★5.0 (157)

Connecticut is moving to eliminate Medicaid coverage of GLP-1 weight loss drugs like Ozempic and Mounjaro, a decision that could leave thousands of residents without access to medications that have transformed obesity

24.18

★★★★★4.7 (84)

Connecticut is moving to eliminate Medicaid coverage of GLP-1 weight loss drugs like Ozempic and Mounjaro, a decision that could leave thousands of residents without access to medications that have transformed obesity

22.45

★★★★★4.9 (203)

Connecticut is moving to eliminate Medicaid coverage of GLP-1 weight loss drugs like Ozempic and Mounjaro, a decision that could leave thousands of residents without access to medications that have transformed obesity

22.35

★★★★★5.0 (176)

Connecticut is moving to eliminate Medicaid coverage of GLP-1 weight loss drugs like Ozempic and Mounjaro, a decision that could leave thousands of residents without access to medications that have transformed obesity

22.60

★★★★★4.8 (132)